284 related articles for article (PubMed ID: 31088836)
1. DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
Travers M; Brown SM; Dunworth M; Holbert CE; Wiehagen KR; Bachman KE; Foley JR; Stone ML; Baylin SB; Casero RA; Zahnow CA
Cancer Res; 2019 Jul; 79(13):3445-3454. PubMed ID: 31088836
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Stone ML; Chiappinelli KB; Li H; Murphy LM; Travers ME; Topper MJ; Mathios D; Lim M; Shih IM; Wang TL; Hung CF; Bhargava V; Wiehagen KR; Cowley GS; Bachman KE; Strick R; Strissel PL; Baylin SB; Zahnow CA
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10981-E10990. PubMed ID: 29203668
[TBL] [Abstract][Full Text] [Related]
3. TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.
Lecker LSM; Berlato C; Maniati E; Delaine-Smith R; Pearce OMT; Heath O; Nichols SJ; Trevisan C; Novak M; McDermott J; Brenton JD; Cutillas PR; Rajeeve V; Hennino A; Drapkin R; Loessner D; Balkwill FR
Cancer Res; 2021 Nov; 81(22):5706-5719. PubMed ID: 34561272
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer.
Heath O; Berlato C; Maniati E; Lakhani A; Pegrum C; Kotantaki P; Elorbany S; Böhm S; Barry ST; Annibaldi A; Barton DP; Balkwill FR
Cancer Immunol Res; 2021 Jun; 9(6):665-681. PubMed ID: 33839687
[TBL] [Abstract][Full Text] [Related]
5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
7. The effect of combination treatment with alpha-difluoromethylornithine and Corynebacterium parvum on B16 melanoma growth and tumoricidal effector cell generation in vivo.
Bowlin TL; Rosenberger AL; Sunkara PS
Cancer Immunol Immunother; 1985; 20(3):214-8. PubMed ID: 3933819
[TBL] [Abstract][Full Text] [Related]
8. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
9. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Moufarrij S; Srivastava A; Gomez S; Hadley M; Palmer E; Austin PT; Chisholm S; Diab N; Roche K; Yu A; Li J; Zhu W; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Sci Rep; 2020 Feb; 10(1):3470. PubMed ID: 32103105
[TBL] [Abstract][Full Text] [Related]
10. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
11. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
12. Astragaloside IV antagonizes M2 phenotype macrophage polarization-evoked ovarian cancer cell malignant progression by suppressing the HMGB1-TLR4 axis.
Wang X; Gao S; Song L; Liu M; Sun Z; Liu J
Mol Immunol; 2021 Feb; 130():113-121. PubMed ID: 33308900
[TBL] [Abstract][Full Text] [Related]
13. Effect of polyamine depletion in vivo by DL-alpha-difluoromethylornithine on functionally distinct populations of tumoricidal effector cells in normal and tumor-bearing mice.
Bowlin TL; McKown BJ; Davis GF; Sunkara PS
Cancer Res; 1986 Nov; 46(11):5494-8. PubMed ID: 3093066
[TBL] [Abstract][Full Text] [Related]
14. The effect of alpha-difluoromethylornithine on natural killer cell and tumoricidal macrophage induction by interferon in vivo.
Bowlin TL; Rosenberger AL; McKown BJ; Davis GF; Sunkara PS
Int J Immunopharmacol; 1986; 8(2):131-6. PubMed ID: 3086243
[TBL] [Abstract][Full Text] [Related]
15. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
16. Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment.
Ren F; Fan M; Mei J; Wu Y; Liu C; Pu Q; You Z; Liu L
Drug Des Devel Ther; 2014; 8():1527-38. PubMed ID: 25284985
[TBL] [Abstract][Full Text] [Related]
17. Combined use of alpha-difluoromethylornithine and an inhibitor of S-adenosylmethionine decarboxylase in mice bearing P388 leukemia or Lewis lung carcinoma.
Nakaike S; Kashiwagi K; Terao K; Iio K; Igarashi K
Jpn J Cancer Res; 1988 Apr; 79(4):501-8. PubMed ID: 3133338
[TBL] [Abstract][Full Text] [Related]
18. Diverse macrophages polarization in tumor microenvironment.
Rhee I
Arch Pharm Res; 2016 Nov; 39(11):1588-1596. PubMed ID: 27562774
[TBL] [Abstract][Full Text] [Related]
19. Effects of three irreversible inhibitors of ornithine decarboxylase on macrophage-mediated tumoricidal activity and antitumor activity in B16F1 tumor-bearing mice.
Bowlin TL; Hoeper BJ; Rosenberger AL; Davis GF; Sunkara PS
Cancer Res; 1990 Aug; 50(15):4510-4. PubMed ID: 2114941
[TBL] [Abstract][Full Text] [Related]
20. Natural killer T cell activation increases iNOS
Paul S; Chhatar S; Mishra A; Lal G
J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
